$150 Million is the total value of Opaleye Management Inc.'s 49 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CHMA | Exit | CHIASMA INC | $0 | – | -20,000 | -100.0% | -0.11% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -18,000 | -100.0% | -0.21% | – |
| NVLS | Exit | NIVALIS THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.26% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -14,000 | -100.0% | -0.36% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -14,500 | -100.0% | -0.42% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -50,000 | -100.0% | -0.43% | – |
| AKAOQ | Exit | ACHAOGEN INC | $0 | – | -255,000 | -100.0% | -0.44% | – |
| XOMA | Exit | XOMA CORP DEL | $0 | – | -1,350,000 | -100.0% | -0.65% | – |
| Exit | PROTEON THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.72% | – | |
| OHRP | Exit | OHR PHARMACEUTICAL INC | $0 | – | -366,000 | -100.0% | -0.73% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -150,000 | -100.0% | -1.28% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -240,000 | -100.0% | -1.38% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -80,000 | -100.0% | -2.11% | – |
| GERN | Exit | GERON CORP | $0 | – | -1,325,000 | -100.0% | -2.41% | – |
| Exit | CYTRX CORP | $0 | – | -1,440,000 | -100.0% | -2.57% | – | |
| DEPO | Exit | DEPOMED INC | $0 | – | -325,000 | -100.0% | -2.82% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -165,000 | -100.0% | -3.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 42 | Q2 2024 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 30 | Q2 2024 | 3.6% |
| OCULAR THERAPEUTIX INC | 27 | Q2 2024 | 17.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| ETON PHARMACEUTICALS INC | 23 | Q2 2024 | 5.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| TG THERAPEUTICS INC | 20 | Q2 2024 | 10.1% |
| CRINETICS PHARMACEUTICALS INC | 20 | Q1 2024 | 5.6% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iBio, Inc. | April 09, 2024 | 650,000 | 7.6% |
| OCULAR THERAPEUTIX, INC | February 14, 2024 | 6,070,000 | 5.5% |
| SANUWAVE Health, Inc. | February 14, 2024 | 115,493,554 | 9.1% |
| HARROW, INC. | February 09, 2024 | 3,820,000 | 10.9% |
| Jounce Therapeutics, Inc.Sold out | February 09, 2024 | 0 | 0.0% |
| Tracon Pharmaceuticals, Inc. | February 09, 2024 | 10 | 0.0% |
| Context Therapeutics Inc. | January 05, 2024 | 820,000 | 5.1% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-26 |
| 4 | 2024-09-23 |
| 4 | 2024-09-19 |
| SC 13G/A | 2024-09-18 |
| 3 | 2024-09-12 |
| 4 | 2024-09-12 |
| 4 | 2024-09-12 |
| SC 13G/A | 2024-09-12 |
| 4 | 2024-09-10 |
| N-PX | 2024-09-03 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.